Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Reiterates Overweight on Stoneridge, Maintains $27 Price Target

Stephens & Co. analyst Justin Long reiterates Stoneridge (NYSE:SRI) with a Overweight and maintains $27 price target.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Stephens & Co. analyst Justin Long reiterates Stoneridge (NYSE:SRI) with a Overweight and maintains $27 price target.

Analyst Ratings

Expert Ratings For Cirrus Logic

By Benzinga Insights

Today, 2:11 AM

Within the last quarter, Cirrus Logic (NASDAQ:CRUS) has observed the following analyst ratings:

CRUS

Tempest Announces Presentation At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting On Nov. 10-14

By Benzinga Newsdesk

Today, 2:11 AM

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of

TPST

Piper Sandler Maintains Underweight on Celanese, Raises Price Target to $145

By Benzinga Newsdesk

Today, 2:11 AM

Piper Sandler analyst Charles Neivert maintains Celanese (NYSE:CE) with a Underweight and raises the price target from $140 to $145.

Why GM’s Stock Is Trading Higher Today

By Randy Elias

Today, 2:11 AM

General Motors Company (NYSE: GM) shares are trading higher after the company announced it will increase its EV and AV investments from 2020 through 2025 to $35 billion, represent

Stephens & Co. Reiterates Overweight on Stoneridge, Maintains $27 Price Target

Related Posts

Expert Ratings For Cirrus Logic

Tempest Announces Presentation At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting On Nov. 10-14

Piper Sandler Maintains Underweight on Celanese, Raises Price Target to $145

Why GM’s Stock Is Trading Higher Today